Blk was identified two decades ago as a B-cell-specific member of the Src family of tyrosine kinases. Recent studies, however, have discovered that Blk is expressed in many cell types outside of the B lineage, including early thymic precursors, interleukin-17-producing cd T cells and pancreatic b-cells. In light of these recent discoveries, we performed a more comprehensive analysis of Blk expression patterns in hematopoietic cells and found that Blk is differentially expressed in mature B-cell subsets, with marginal zone (MZ) B cells expressing high levels, B1 B cells expressing intermediate-to-high levels and follicular (FO) B cells expressing low levels of Blk. To determine whether these differences in Blk expression levels reflected differential requirements for Blk in MZ, B1 and FO B-cell development, we analyzed the effects of reducing and eliminating Blk expression on B-cell development. We report that both Blk haploinsufficiency and Blk deficiency impaired the generation of MZ B cells. Moreover, although there were fewer MZ B cells in Blk +/À and Blk À/À mice as compared with Blk +/+ mice, Blk-mutant MZ B cells were hyper-responsive to B-cell receptor stimulation, both in vitro and in vivo. Thus, this study has revealed a previously unappreciated role for Blk in the development and activation of MZ B cells.
Members of the Src family of tyrosine kinases (SFKs) are activated in response to many different stimuli and, consequently, are involved in a multitude of signaling pathways. 1, 2 SFKs are expressed in both hematopoietic and non-hematopoietic cells; however, some family members show a restricted pattern of expression in hematopoietic cells. 1, 2 Lck and Blk are examples of SFKs whose expression has been reported to be restricted to specific hematopoietic lineages; Lck is expressed in T-lineage cells whereas Blk is expressed in B-lineage cells. [1] [2] [3] However, in contrast to Lck, which has an essential, nonredundant role in T-cell development, 4 Blk was shown to be dispensable for B-cell development. 5 Based on these findings, it was concluded that Lyn and Fyn, two broadly expressed SFKs that are found in B-lineage cells, could compensate for the loss of Blk during B-cell development. 5 Although Blk was initially thought to be a B-cell-specific SFK, recent studies have shown that it is expressed in a variety of cell types outside of the B-cell lineage. 6, 7 One group found Blk to be expressed in both human and mouse pancreatic b-cells, where, in response to glucose, it enhances insulin synthesis and secretion. 6 Notably, mutations in BLK, which act to reduce Blk activity and/or expression, have been identified in patients with maturity-onset diabetes of the young, a form of diabetes characterized by an autosomal pattern of inheritance and an early age at onset. 6 In addition, we discovered that Blk is expressed in progenitor populations from the bone marrow (BM) and thymus, in immature thymocytes, in gd thymocytes and in a small subset of mature gd T cells that have the potential to produce the proinflammatory cytokine interleukin-17 (IL-17). 7 Importantly, Blk is required for the development of T cells and IL-17-producing gd T cells, as Blk-deficient mice show reduced thymus cellularity during ontogeny and generate significantly fewer IL-17-producing gd T cells than wild-type (Blk-sufficient) mice. 7 In light of the discovery that the expression pattern of Blk is much broader than initially reported, we sought to perform a more comprehensive analysis of Blk expression levels in hematopoietic cells using our recently developed intracellular (i.c.) flow-cytometric assay. During this analysis, as a consequence of using B-cell subsets as positive staining controls for Blk, we noted that Blk is differentially expressed in mature B-cell subsets. Specifically, Blk was found to be expressed at high levels in marginal zone (MZ) B cells, at intermediate-to-high levels in B1 B cells and at low levels in follicular (FO) B cells. To determine whether these differences in Blk expression levels reflected differential requirements for Blk in MZ, B1 and FO B-cell development, we analyzed the effects of reducing Blk levels on B-cell development in mice expressing one functional allele of Blk (Blk +/À ). In addition, we analyzed Blk À/À mice, as the effects of Blk deficiency on MZ B-cell development have not been examined previously. 5 Here, we report that both reducing and eliminating Blk expression impaired the development of MZ B cells. Paradoxically, although there were fewer MZ B cells in Blk +/À and Blk À/À mice as compared with Blk +/+ mice, Blk-mutant MZ B cells were hyper-responsive to B-cell receptor (BCR) stimulation, both in vitro and in vivo. Lastly, we found that, with age, Blk +/À and Blk À/À mice show a breach in B-cell tolerance, as evidenced by the detection of serum anti-nuclear Abs (ANAs). Thus, Blk joins the list of signaling molecules that are required for the development and activation of MZ B cells.
RESULTS

Blk is differentially expressed in mature B-cell subsets
We recently developed an i.c. flow-cytometric assay to measure Blk protein expression at the single-cell level. 7 Using this assay, we found that Blk is detected in pre-pro-B cells, the earliest identifiable B-cell precursors in the BM, and that its expression continues to increase as B-lineage cells mature through the pro-B and pre-B stages to reach the immature B-cell stage (Figures 1a and b) . In contrast to the BM, where Blk expression levels were upregulated during differentiation, Blk expression levels in splenic B-cell subsets were, for the most part, downregulated in comparison. Immature B cells that are generated in the BM migrate to the spleen, where they mature and become transitional (T) B cells. T B cells in turn give rise either to mature MZ B cells, through intermediates known as MZ precursors (MZPs), or to mature FO-I B cells. A second type of FO B cell, known as the FO-II B cell, has recently been described. 8 FO-II B cells share functional abilities with FO-I B cells (that is, T-dependent humoral responses) but differ from FO-I B cells in their developmental requirements and in their ability to serve as precursors to both MZ B cells and FO-I B cells. 8 The splenic B-cell subsets that expressed Blk at levels lower than those in immature B cells were the T, FO-II and FO-I B-cell subsets (Figures 1a and b) . By contrast, MZPs and MZ B cells expressed Blk at levels comparable to or higher than those in immature B cells (Figures 1a and b) . As MZ B cells are the progeny of T and/or FO-II B cells, [8] [9] [10] [11] In addition, we measured Blk expression levels in B1 B cells, a second B-cell lineage that resides primarily in the peritoneal and pleural cavities. Interestingly, both B1a and B1b B-cell subsets in the peritoneal cavity (PerC) expressed Blk at relatively high levels, whereas the resident B2 B cells expressed Blk at levels comparable to those observed in splenic FO-I B cells (Figures 1a and b ). These data demonstrate that Blk is differentially expressed in mature B-cell subsets, with MZ B cells expressing the highest levels of Blk, followed by B1 B cells and then by FO B cells.
Impaired MZ B-cell development in Blk +/À and Blk À/À mice The difference in Blk expression levels between MZ and FO B cells suggested a difference in the requirement for Blk in MZ and FO B-cell development. To test this, we analyzed splenic B-cell development in not only Blk À/À mice but also Blk +/À mice, as their B cells have reduced levels of Blk (55% of wild-type B cells (Figure 2) ). Using various gating strategies, 8, 12, 13 we noted significant differences in the relative percentages and absolute numbers of several splenic B-cell subsets in Blk +/+ , Blk +/À and Blk À/À mice (Figures 3a and b, and Table 1 ). First, we found that the percentages and numbers of both MZPs and MZ B cells were dramatically decreased in Blk +/À and Blk À/À mice as compared with Blk +/+ mice. Remarkably, the percentage and number of FO-I B cells were similar among all three genotypes, indicating that reducing or eliminating Blk expression impairs the development of MZ but not FO-I B cells. Interestingly, we also found that the percentages and numbers of T1 and FO-II B cells were significantly increased in Blk +/À and Blk À/À mice. As these B-cell subsets are precursors to both MZ and FO-I B cells, [8] [9] [10] [11] the increase in their numbers in Blk +/À and Blk À/À mice suggests that reducing or eliminating Blk blocks MZ B-cell development at an early stage in the FO versus MZ B-cell fate decision.
Peritoneal B1 B-cell numbers are increased in Blk À/À but not Blk +/À mice Our expression study also demonstrated that B1 B cells express higher levels of Blk than FO-I B cells (Figure 1b) . To determine whether B1 B cells require relatively high levels of Blk for their development, we performed flow-cytometric analysis on PerC cells from both Blk +/À and Blk À/À mice. We found that reducing Blk levels did not affect B1 B-cell development, as the percentages and numbers of B1a and B1b B-cell subsets were comparable in Blk +/+ and Blk +/À mice ( Figure 3c and Table 2 ). Blk deficiency, on the other hand, did affect B1 B-cell development. There were marked increases in not only the relative percentages of B1a and B1b B cells but also the absolute numbers of these B1 subsets, as a result of the significant increase in the overall cellularity of the PerC in Blk À/À mice as compared with Blk +/+ mice ( Figure 3c and Table 2 ). Therefore, even though both MZ and B1 B cells express relatively high levels of Blk as compared with FO-I B cells, Blk deficiency has opposite effects on their development, with Blk À/À mice generating fewer MZ B cells but more B1 B cells than Blk +/+ mice. Blk haploinsufficiency, by contrast, only affected the generation of MZ B cells. Together, these data underscore differences in the developmental requirements of MZ and B1 B cells.
Humoral responses to a T-independent antigen are enhanced in Blk +/À and Blk À/À mice Several mutant mouse strains with reduced numbers of MZ B cells exhibit impaired responses to T-independent antigens. [14] [15] [16] [17] [18] [19] Because MZ B-cell numbers are reduced in Blk +/À and Blk À/À mice, it was of interest to determine whether their functional response to a Tindependent antigen was also impaired. Because the MZ B-cell compartment is specifically targeted when T-independent antigens are injected intravenously, 20 we immunized Blk +/+ , Blk +/À and Blk À/À mice with NP (4-hydroxy-3-nitrophenylacetic)-Ficoll, a type-2 T-independent antigen, by this route. Surprisingly, we found that the serum levels of NP-specific Ig were increased in both Blk +/À and Blk À/À mice as compared with Blk +/+ mice, albeit not significantly ( Figure 4 ). Furthermore, even though serum levels of NP-specific IgM were equivalent among the three genotypes, the serum levels of NP-specific IgG1 were significantly higher in Blk +/À and Blk À/À mice than in Blk +/+ mice ( Figure 4 ). These findings demonstrate that MZ B cells in Blk +/À and Blk À/À mice exhibit an enhanced humoral response to a T-independent antigen.
We also evaluated the ability of Blk +/À and Blk À/À mice to produce Abs in response to a T-dependent antigen (that is, NP-OVA). Blk +/+ , Blk +/À and Blk À/À mice were immunized with alum-precipitated NP-OVA and, 14 days later, their sera were collected and analyzed. No significant differences were observed among Blk +/+ , Blk +/À and Blk À/À mice in their serum levels of NP-specific Ig, IgM or IgG1 (data not shown). Thus, these results demonstrate that Blk haploinsufficiency and Blk deficiency have no appreciable effects on the humoral response to a T-dependent antigen.
MZ B cells from Blk +/À and Blk À/À mice are hyper-responsive to BCR stimulation To understand how Blk +/À and Blk À/À mice could mount a robust humoral response to NP-Ficoll with significantly fewer MZ B cells than Blk +/+ mice, we evaluated the effects of Blk haploinsufficiency and Blk deficiency on B-cell activation in vitro. We first compared the ability of MZ and FO B cells from Blk +/+ , Blk +/À and Blk À/À mice to upregulate CD86 expression following Ab-mediated cross-linking of IgM. Notably, we observed striking differences in the CD86 expression levels on activated MZ B cells from wild-type and Blk-mutant mice, with Blk +/À and Blk À/À MZ B cells expressing, on average, 1.7-fold higher levels of CD86 than Blk +/+ MZ B cells following activation with anti-IgM (Figures 5a and c) . By contrast, no differences were detected among FO B cells from the three genotypes in their surface levels of CD86 following BCR stimulation (Figure 5a ). Instead, we found that the percentages of Blk +/À and Blk À/À FO B cells with increased CD86 expression were consistently higher than that of wild-type FO B cells across the concentration range of anti-IgM used to simulate antigen-BCR ligation (Figures 5a and b) . The enhanced ability of B cells from Blk +/À and Blk À/À mice to respond to the low doses of anti-IgM indicate that both Blk haploinsufficiency and Blk deficiency lower the threshold of B-cell activation. (Figures 7c and d) . MZ B-cell numbers were significantly higher in aged Blk +/À and Blk À/À mice than in young (2-month-old) Blk +/À and Blk À/À mice (Figure 7c ). In fact, the number of MZ B cells in aged Blk +/À mice was even higher than that in aged Blk +/+ mice, whereas that in aged Blk À/À mice was still lower than that in aged Blk +/+ mice (Figure 7c ). In aged Blk +/À mice, we also noted a significant increase in B1 B-cell numbers relative to aged Blk +/+ mice as well as to young Blk +/À mice (Figure 7d ). The number of B1 B cells in aged Blk À/À mice, on the other hand, was unchanged as compared with young Blk À/À mice. These data demonstrate that there are age-related changes in the phenotype and number of the MZ and B1 B-cell populations in Blk +/À and Blk À/À mice. Because MZ and B1 B cells are known to be a source of autoantibodies, [28] [29] [30] [31] [32] we assayed the sera of aged Blk +/À and Blk À/À mice for the presence of autoantibodies. We found that the serum levels of ANAs were significantly higher in 6-month-old Blk +/À mice than in age-matched Blk +/+ mice (Pp0.001; Figure 7e ). Although the serum ANA levels were also increased in 6-month-old Blk À/À mice relative to age-matched Blk +/+ mice (Pp0.05; Figure 7e ), there was variability in the serum ANA levels among the individual aged Blk À/À mice. Accordingly, using the wild-type mean OD 450 value plus 2 standard deviations as the upper limit of the normal range, we were able to classify 70% of Blk +/À mice and 27% of Blk À/À mice as autoantibody producers. Therefore, when Blk expression is reduced and, to a lesser extent, absent, there is a breach in B-cell tolerance.
DISCUSSION
Two decades ago, Blk emerged on the scene as an SFK expressed primarily in B cells. 3 Blk, like Lyn and Fyn (the other two major SFKs expressed in B-lineage cells), was shown to be physically associated with the BCR complex and to be activated following BCR engagement. [33] [34] [35] Notably, out of all three SFKs, Blk showed the strongest activation index following BCR cross-linking, suggesting that it was the predominant SFK in the BCR-coupled signaling pathway. 33, 36 Further studies showed that, following BCR stimulation, all three SFKs phosphorylate distinct substrates 37 and differ in their ability to bind to signaling intermediates in the BCR signaling cascade. [36] [37] [38] It was, therefore, a surprise when no apparent defects in B-cell development or activation were observed in Blk À/À mice. 5 As a result, very few groups continued to study Blk, and its functions and mechanisms of action remain poorly defined. There has been a renewed interest in Blk in light of recent studies showing that Blk is not only expressed in non-B-lineage cells but is also indispensable for the development and/or function of these cells. 6, 7 Accordingly, we performed a more comprehensive analysis of Blk expression patterns in hematopoietic cells with the goal of identifying other hematopoietic lineages that express Blk. During this analysis, while using B-cell subsets as positive staining controls, we found that Blk is differentially expressed among MZ, FO B cells. The studies that compared Blk expression between MZ and FO B cells did not report a difference in its expression between these two subsets. 39, 40 An explanation for this discrepancy is that, in the study that compared gene expression in MZ and FO B cells following microarray analysis, differential expression between the two subsets was restricted to a mean fold change of 42. 39 The results of our flow assay demonstrated a two-fold difference in Blk expression between MZ and FO B cells, which falls below the 42-fold limit set up in the microarray study. To explain the results from the biochemical study that reported no difference in Blk protein expression between MZ and FO B cells by western blot analysis, 40 we propose that lysis in the detergent NP-40 did not solubilize all the cellular compartments where Blk is associated in MZ B cells. Our flow assay, on the other hand, detects Blk in any cellular compartment, as long as the epitope is available for binding.
Our re-examination of the role of Blk in B-cell development and activation demonstrated that a loss of Blk expression affected MZ and B1-B cell development, as well as humoral responses to a T-independent antigen. These findings are in stark contrast to those of the initial study that reported that Blk À/À mice show no defects in B-cell development and function. 5 An explanation for the contradictory results is that the initial study was published a decade ago, prior to the development of the complex gating strategies that are used to identify MZPs and MZ B cells. 8, 13, 41 In point of fact, there was no quantification of MZPs and MZ B cells in the original report. 5 Another explanation, which is not mutually exclusive, is that the different genetic backgrounds of the Blk À/À mice used in the two studies (that is, 129/Sv in the first study and C57BL/6 in our study) differentially modify the effects of Blk deficiency. Consistent with this explanation are the reports that Fyn deficiency has different effects on T-cell activation and function depending on the genetic background of the Fyn À/À mouse. [42] [43] [44] [45] SFKs can be positive or negative regulators of cell signaling (reviewed in Lowell 1 , Palacios and Weiss 2 and Salmond et al. 46 ). The finding that B cells from Blk +/À and Blk À/À mice are hyperresponsive to BCR stimulation, as evidenced by their enhanced ERK activation and cellular proliferation, indicate that Blk negatively regulates the BCR signaling response. Based on these findings, we propose that the activation threshold of a B cell is proportionate to its cellular level of Blk. This idea is supported by the comparison of the proliferative responses of wild-type MZ and FO B cells, in which Blk lo FO B cells out-proliferate Blk hi MZ B cells following BCR stimulation 10 ( Figure 4d) .
Assigning Blk the role as a negative regulator of BCR signal transduction has important implications for B-cell subset fate decisions. Evidence is accumulating to support a role for BCR signal strength in the generation of B1, FO and MZ B cells, although it is not clear whether BCR signal strength determines cell fate, maintains the cell fate decision or both (reviewed in Pillai and Cariappa, 9 Martin and Kearney, 10 Lopes-Carvalho and Kearney 26 and Hardy 47 ). According to the current model, a strong signal is required for the generation of B1 B cells, an intermediate-to-strong signal is required for the generation of FO B cells and a weak signal is required for the generation of MZ B cells. Our data support this model, as Blk deficiency, which augments the BCR signaling response, resulted in an increased number of B1 cells and a decreased number of MZ B cells. Interestingly, FO-I B-cell numbers were not significantly different between Blk +/+ and Blk À/À mice, suggesting that the effects that Blk deficiency has on the BCR signaling response are still within the range allowed for FO B-cell generation and/or survival.
Blk as a negative regulator of BCR signal transduction also has important implications in the control of B-cell tolerance. Both B1 B cells and MZ B cells express relatively high levels of this negative regulator as compared with FO B cells. As MZ and B1 B cells are positively selected by self-antigens (reviewed in Pillai and Cariappa, 9 Martin and Kearney, 10 Lopes-Carvalho and Kearney 26 and Hardy 47 ), their relatively high expression of Blk may be a mechanism by which a high BCR signaling threshold is set in these potentially self-reactive cells. This proposed mechanism may explain why, when signaling thresholds are lowered as a result of reduced Blk levels, there is a breach in tolerance, as evidenced by the detection of ANAs in aged Blk +/À mice. We posit that the expanded MZ and B1 B-cell populations, both of which are known to be a source of autoantibodies, [28] [29] [30] [31] [32] contribute to the elevated serum levels of ANAs in aged Blk +/À mice. Along these lines, the finding that fewer aged Blk À/À mice than Blk +/À mice produce ANAs may be explained by the fact that their MZ B-cell numbers, although increased as compared with young Blk À/À mice, are approximately 50% of those in Blk +/À mice. Thus, we predict that the percentage of Blk À/À mice with elevated serum levels of ANAs will increase with age, providing their MZ B-cell numbers continue to increase.
An allele in the promoter region of BLK, which results in its reduced transcription, is one of the novel genetic alleles that were recently shown to associate with susceptibility to systemic lupus erythematosus. 48 Our study of Blk-haploinsufficient mice, in which Blk expression levels are reduced to levels comparable to those in individuals homozygous for the risk allele, 48 should provide insight into how this genetic variant promotes the development of systemic lupus erythematosus. However, it is important to note that this risk allele, as it is located in a promoter region, also affects the transcription of an adjacent gene, C8orf13, which is ubiquitously expressed and currently has no known function. 48 Interestingly, the risk allele has the inverse effect on C8orf13 transcription, with B cells from individuals homozygous for the risk allele expressing twice as much C8orf13 message as B cells from individuals lacking the risk allele. 48 Although it is not known whether changes in the expression of both gene products are required to confer susceptibility to systemic lupus erythematosus, it is clear that reducing Blk levels alone can result in a breach in tolerance and autoimmunity.
In summary, we have discovered that Blk is required not only for the development and activation of MZ B cells, but also for the control of B-cell tolerance. 
METHODS Mice
C57BL/6J (Blk +/+ ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA), whereas B6-Blk tm1 (Blk À/À ) mice 5 were provided by A Tarakhovsky (Rockefeller University, New York, NY, USA). All mice used in this study were bred and maintained in the Department of Laboratory Animal Resources at SUNY Upstate Medical University in accordance with the specifications of the Association for Assessment and Accreditation of Laboratory Animal Care. Mouse protocols were approved by the SUNY Upstate Medical University Committee on the Humane Use of Animals. All mice were used at 6-10 weeks of age unless otherwise noted.
Abs and reagents
The monoclonal Abs used for flow-cytometric analysis and magnetic bead separation included anti-CD1d (1B1), anti-CD4 (RM4-5), anti-CD5 (53-7.3), anti-CD8a (53-6.7), anti-CD11b (M1/70), anti-CD19 (6D5), anti-CD21 (7E9), anti-CD23 (B3B4), anti-CD43 (S7), anti-B220 (RA3-6B2), anti-CD86 (GL-1), anti-CD93 (AA4.1), anti-CD117 (2B8), anti-I-Ab (AF6-120.1), and anti-IgM (RMM-1), anti-IgD (11-26c.2a), anti-TCRb (H57-597), anti-TCRgd (UC7-13D5), anti-Gr-1 (RB6-8C5), anti-NK1.1 (PK136) and anti-TER-119 (TER-119), which were purchased from BioLegend (San Diego, CA, USA), eBioscience (San Diego, CA, USA) and BD Pharmingen (San Jose, CA, USA). The Abs used in i.c. flow-cytometric assays were anti-Blk (Cell Signaling Technology, Danvers, MA, USA), fluorescein isothiocyanate-conjugated donkey anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) and anti-phosphoERK1/2 (BD Pharmingen).
Purification of splenic B cells
Splenic B cells were purified by negative selection using magnetic bead separation. Briefly, spleen cells from Blk +/+ , Blk +/À and Blk À/À mice were stained for 10 min with fluorescein isothiocyanate-conjugated anti-CD4; anti-CD8; anti-TCRb; anti-TCRgd; anti-NK1.1; anti-CD11b; anti-Gr-1 and anti-TER-119 monoclonal Abs, washed and then incubated with anti-fluorescein isothiocyanate beads (Miltenyi, Auburn, CA, USA) for 15 min, with all steps at 4 1C. The purity of the resulting cell population was typically X95% CD19 + , as assessed by flow-cytometric analysis.
B-cell activation assays
Splenic B cells were purified by negative selection and then labeled with CFSE (eBioscience) as per the manufacturer's instructions. A total of 3Â10 6 B cells were plated and then stimulated with 10 mg ml À1 goat anti-mouse F(ab¢) 2 antiIgM (Jackson ImmunoResearch, West Grove, PA, USA) and/or 1 mg ml À1 anti-CD40 monoclonal Ab (1C10; BioLegend). Seventy-two hours later, B cells were harvested, stained with monoclonal Abs against various surface antigens and then analyzed by flow-cytometric analysis.
To assess activation marker upregulation after BCR stimulation, 3Â10 6 splenocytes were plated and then stimulated with varying doses (1.25, 2.5, 5 and 10mg ml À1 ) of goat anti-mouse F(ab¢) 2 anti-IgM (Jackson ImmunoResearch). Twenty-four hours later, cells were harvested, stained with monoclonal Abs against various surface antigens, including anti-CD86, and then analyzed by flow-cytometric analysis.
To assess the kinetics of ERK activation after BCR stimulation, 2Â10 6 splenocytes were stimulated for different time periods with 10 mg ml À1 of goat anti-mouse F(ab¢) 2 anti-IgM (Jackson ImmunoResearch); stained with monoclonal Abs against various surface antigens in addition to anti-pERK; and then analyzed by flow-cytometric analysis.
Flow-cytometric analysis
Flow-cytometric analysis for both surface and i.c. antigens was performed as described previously. 7, 49, 50 Western blot analysis B cells were lysed in a buffer containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , protease inhibitors (Roche Laboratories, Indianapolis, IN, USA) and 1% NP-40 Alternative (EMD Biosciences, La Jolla, CA, USA). Proteins within the cleared B-cell lysates were resolved by sodium dodecyl sulfate-PAGE; transferred to polyvinylidene difluoride membranes and blotted with Abs against the N-terminus of Blk (Santa Cruz Biotechnology, Santa Cruz, CA, USA), the C-terminus of Blk (Cell Signaling Technology) and b-actin (Sigma Aldrich, St Louis, MO, USA).
Immunizations and NP-specific ELISAs
To measure humoral responses to a type-2 T-independent antigen, mice were immunized intravenously with 10 mg NP-Ficoll (Biosearch Technologies, Novato, CA, USA). Sera were collected 7 days after immunization.
Serially diluted serum samples were plated in duplicate onto ELISA plates that had been coated with NP 26 -BSA (Biosearch Technologies). NP-specific Igs were identified with horseradish peroxidase-conjugated isotype-specific Abs (SouthernBiotech, Birmingham, AL, USA). Data are presented as OD 450 readings for all serum dilutions.
Autoantibody ELISA
Serum levels of anti-nuclear autoantibodies (ANAs) were measured by ELISA using a kit from Alpha Diagnostics International (San Antonio, TX, USA), following the manufacturer's instructions.
